Clinical study on the using methods of cisplatin in lung cancer chemotherapy
- VernacularTitle:肺癌化疗中顺铂用药方法的临床研究
- Author:
Li REN
1
;
Mei HOU
;
Deyun LUO
;
Hui CHEN
;
Jianping HE
Author Information
1. The First University Hospital West China University of Medical Sciences
- From:
Chinese Journal of Lung Cancer
2001;4(3):200-202
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the therapeutic effectiveness and toxicity between 1-day perfusion and 3-day perfusion of high-dose cisplatin combined chemotherapy for lung cancer. Methods Sixty-four cases of pathologically proved lung cancer were randomized into groups A and B. Group A (32 cases) received cisplatin at d1, and group B (32 cases) received cisplatin at d1-3. Total dosages of cisplatin were same for both groups (100*!mg／m2). Results Delayed vomiting in group B (40.63％) was significantly lower than that of group A (53.13％) (P＜0.05); the early nephrotoxicity rate of group B(25.00％) was lower than that of group A (46.88％), but there was no statistically significant difference between two groups (P＞0.05). The therapeutical response was 62.50％ in group A, and 68.75％ in group B. No significant difference of the chemotherapeutical response was observed between the two groups (P＞0.05). Conclusion In the combined chemotherapy of lung cancer, the division administration of high-dose cisplatin can not only guarantee the therapeutic response, but also abate the gastrotoxicity and the nephrotoxicity of cisplatin.
